Munich, Germany

Dominik Ter Meer



 

Average Co-Inventor Count = 3.9

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2018-2020

Loading Chart...
Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Dominik Ter Meer: Innovator in Fc Gamma Receptor Research

Introduction

Dominik Ter Meer is a prominent inventor based in Munich, Germany. He has made significant contributions to the field of biochemistry, particularly in the study of Fc gamma receptors. With a total of four patents to his name, Ter Meer's work has the potential to impact various therapeutic applications.

Latest Patents

One of his latest patents is an in vitro method for determining the stability of compositions comprising soluble Fc gamma receptors. This invention focuses on assessing the shelf stability and overall stability of these compositions through a series of detailed steps involving human IgG. Another notable patent involves a vector encoding an Fc gamma receptor IIB protein, which includes a nucleic acid sequence and its applications in pharmaceutical compositions.

Career Highlights

Dominik Ter Meer is currently employed at Suppremol GmbH, where he continues to advance his research in immunology and biochemistry. His innovative approaches have garnered attention in the scientific community, contributing to the understanding of receptor interactions and their implications in health.

Collaborations

Throughout his career, Ter Meer has collaborated with esteemed colleagues such as Peter Sondermann and Thomas Pohl. These partnerships have fostered a collaborative environment that enhances the research and development of new therapeutic solutions.

Conclusion

Dominik Ter Meer's work exemplifies the intersection of innovation and scientific research in the field of Fc gamma receptors. His contributions through patents and collaborations continue to pave the way for advancements in biochemistry and therapeutic applications.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…